Literature DB >> 33415432

Role of [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET/CT.

Liang Zhao1,2, Yizhen Pang1, Zuoming Luo1, Kaili Fu2, Tingting Yang2, Long Zhao1, Long Sun1, Hua Wu1, Qin Lin3, Haojun Chen4.   

Abstract

PURPOSE: The aim of this study was to explore the role of [68Ga]Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT), compared with 18F-fluorodeoxyglucose [18F]-FDG PET/CT, for evaluating peritoneal carcinomatosis in patients with various types of cancer.
METHODS: Patients with suspected peritoneal malignancy, who underwent both [18F]-FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT between October 2019 and August 2020, were retrospectively analysed. The radiotracer uptake, peritoneal cancer index (PCI) score, and diagnostic performance of [18F]-FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT were evaluated and compared.
RESULTS: Our cohort consisted of 46 patients, including 16 patients with diffuse-type peritoneal carcinomatosis, 27 with nodular-type peritoneal carcinomatosis, and 3 true-negative patients. A significant difference in standard uptake values (SUV) of lesions between [18F]-FDG and [68Ga]Ga-DOTA-FAPI-04 PET/CT examination was observed (median SUV: 3.48 vs. 9.82; P < 0.001), particularly in peritoneal carcinomatosis from gastric cancer (median SUV: 3.44 vs. 8.05; P = 0.001). Moreover, [68Ga]Ga-DOTA-FAPI-04 PET/CT showed a higher PCI score and better sensitivity than [18F]-FDG PET/CT for the detection of peritoneal carcinomatosis (6 vs. 18; P < 0.001; 72.09% vs. 97.67%; P = 0.002).
CONCLUSION: [68Ga]Ga-DOTA-FAPI-04 PET/CT demonstrated superior sensitivity over [18F]-FDG PET/CT for the detection of peritoneal carcinomatosis in patients with various types of cancer, particularly gastric cancer. Furthermore, the uptake of [68Ga]Ga-DOTA-FAPI-04 in peritoneal carcinomatosis was significantly higher than that of [18F]-FDG, demonstrating a larger extent of the lesions and yielding a higher PCI score. This could help enhance the image contrast, improve physicians' diagnostic confidence, and reduce the proportion of missed diagnoses.

Entities:  

Keywords:  PET/CT; Peritoneal cancer index; Peritoneal carcinomatosis; [18F]-FDG; [68Ga]Ga-DOTA-FAPI-04

Mesh:

Substances:

Year:  2021        PMID: 33415432     DOI: 10.1007/s00259-020-05146-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  33 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

2.  Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures.

Authors:  O Glehen; D Osinsky; E Cotte; F Kwiatkowski; G Freyer; S Isaac; V Trillet-Lenoir; A C Sayag-Beaujard; Y François; J Vignal; F N Gilly
Journal:  Ann Surg Oncol       Date:  2003-10       Impact factor: 5.344

3.  64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings.

Authors:  Daniele Marin; Carlo Catalano; Mahbubeh Baski; Michele Di Martino; Daniel Geiger; Angelo Di Giorgio; Simone Sibio; Roberto Passariello
Journal:  Abdom Imaging       Date:  2009-05-20

4.  Intraperitoneal contrast material combined with CT for detection of peritoneal metastases of ovarian cancer.

Authors:  S Gryspeerdt; L Clabout; L Van Hoe; P Berteloot; I B Vergote
Journal:  Eur J Gynaecol Oncol       Date:  1998       Impact factor: 0.196

Review 5.  Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications.

Authors:  Mohammad Alyami; Martin Hübner; Fabian Grass; Naoual Bakrin; Laurent Villeneuve; Nathalie Laplace; Guillaume Passot; Olivier Glehen; Vahan Kepenekian
Journal:  Lancet Oncol       Date:  2019-07       Impact factor: 41.316

6.  Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.

Authors:  P H Cashin; H Mahteme; N Spång; I Syk; J E Frödin; M Torkzad; B Glimelius; W Graf
Journal:  Eur J Cancer       Date:  2016-01-02       Impact factor: 9.162

Review 7.  Peritoneal Metastases in Colorectal Cancer.

Authors:  Richard Jacobson; Scott K Sherman; Fadi Dahdaleh; Kiran K Turaga
Journal:  Ann Surg Oncol       Date:  2018-05-10       Impact factor: 5.344

Review 8.  Staging of pancreatic ductal adenocarcinoma with spiral CT and MRI.

Authors:  M G Brizi; L Natale; R Manfredi; B Barbaro; A Vecchioli; P Marano
Journal:  Rays       Date:  2001 Apr-Jun

Review 9.  MR imaging of the peritoneal spread of malignancy.

Authors:  Russell N Low
Journal:  Abdom Imaging       Date:  2007 May-Jun

Review 10.  Clinical role of FDG PET in evaluation of cancer patients.

Authors:  Lale Kostakoglu; Harry Agress; Stanley J Goldsmith
Journal:  Radiographics       Date:  2003 Mar-Apr       Impact factor: 5.333

View more
  16 in total

1.  Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer.

Authors:  Yizhen Pang; Long Zhao; Qihang Shang; Tinghua Meng; Liang Zhao; Liuxing Feng; Shuangjia Wang; Ping Guo; Xiurong Wu; Qin Lin; Hua Wu; Weipeng Huang; Long Sun; Haojun Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

2.  Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management.

Authors:  Chunxia Qin; Yangmeihui Song; Yongkang Gai; Weiwei Ruan; Qingyao Liu; Fang Liu; Danzha Zheng; Peng Zhang; Hongli Liu; Tao Zhang; Kaixiong Tao; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-06-03       Impact factor: 10.057

Review 3.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

4.  [68Ga]Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F]FDG PET/CT.

Authors:  Rong Lin; Zefang Lin; Zhenying Chen; Shan Zheng; Jiaying Zhang; Jie Zang; Weibing Miao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-25       Impact factor: 10.057

5.  State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis.

Authors:  Martina Sollini; Margarita Kirienko; Fabrizia Gelardi; Francesco Fiz; Noemi Gozzi; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-25       Impact factor: 9.236

6.  Fibroblast activation protein identifies Consensus Molecular Subtype 4 in colorectal cancer and allows its detection by 68Ga-FAPI-PET imaging.

Authors:  Esther Strating; Emma Wassenaar; Mathijs Verhagen; Paulien Rauwerdink; Susanne van Schelven; Ignace de Hingh; Inne Borel Rinkes; Djamila Boerma; Arjen Witkamp; Miangela Lacle; Riccardo Fodde; Richard Volckmann; Jan Koster; Kris Stedingk; Frederik Giesel; Remmert de Roos; Alex Poot; Guus Bol; Marnix Lam; Sjoerd Elias; Onno Kranenburg
Journal:  Br J Cancer       Date:  2022-03-16       Impact factor: 9.075

Review 7.  Peritoneal Metastases From Colorectal Cancer: Defining and Addressing the Challenges.

Authors:  Onno Kranenburg; Kurt van der Speeten; Ignace de Hingh
Journal:  Front Oncol       Date:  2021-03-16       Impact factor: 6.244

8.  Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F]F-FDG in Oncology: A Systematic Review.

Authors:  Giorgio Treglia; Barbara Muoio; Hessamoddin Roustaei; Zahra Kiamanesh; Kamran Aryana; Ramin Sadeghi
Journal:  Int J Mol Sci       Date:  2021-10-17       Impact factor: 5.923

9.  Dual-Energy Computed Tomography-Based Radiomics to Predict Peritoneal Metastasis in Gastric Cancer.

Authors:  Yong Chen; Wenqi Xi; Weiwu Yao; Lingyun Wang; Zhihan Xu; Michael Wels; Fei Yuan; Chao Yan; Huan Zhang
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

Review 10.  FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.

Authors:  Tianshuo Yang; Long Ma; Haodong Hou; Feng Gao; Weijing Tao
Journal:  Front Oncol       Date:  2022-01-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.